Media stories about CombiMatrix (NASDAQ:CBMX) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CombiMatrix earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.4939962391177 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Separately, Ladenburg Thalmann Financial Services downgraded CombiMatrix from a “buy” rating to a “neutral” rating in a research note on Friday, August 4th.

Shares of CombiMatrix (NASDAQ CBMX) traded down $0.20 during mid-day trading on Thursday, reaching $6.25. The company had a trading volume of 51,800 shares, compared to its average volume of 119,111. CombiMatrix has a 1 year low of $2.20 and a 1 year high of $8.20. The company has a current ratio of 3.23, a quick ratio of 3.03 and a debt-to-equity ratio of 0.02.

CombiMatrix (NASDAQ:CBMX) last announced its earnings results on Monday, November 6th. The medical research company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.03. CombiMatrix had a negative return on equity of 27.90% and a negative net margin of 13.19%. The firm had revenue of $4.01 million for the quarter, compared to the consensus estimate of $4.19 million. During the same period in the previous year, the business earned ($0.38) EPS. equities research analysts forecast that CombiMatrix will post -0.59 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at

About CombiMatrix

CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies.

Insider Buying and Selling by Quarter for CombiMatrix (NASDAQ:CBMX)

Receive News & Ratings for CombiMatrix Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.